Sage Rhino Capital LLC Buys 5,041 Shares of Gilead Sciences, Inc. $GILD

Sage Rhino Capital LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 213.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,400 shares of the biopharmaceutical company’s stock after buying an additional 5,041 shares during the period. Sage Rhino Capital LLC’s holdings in Gilead Sciences were worth $821,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. GoalVest Advisory LLC boosted its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the third quarter valued at about $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences in the second quarter valued at about $27,000. Putney Financial Group LLC raised its stake in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences in the second quarter worth about $30,000. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wolfe Research reissued an “outperform” rating and issued a $150.00 price objective on shares of Gilead Sciences in a research note on Monday, December 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the company an “outperform” rating in a research note on Monday, December 29th. Daiwa Capital Markets raised their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, TD Cowen boosted their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $133.52.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $135.93 on Monday. The company has a market capitalization of $168.65 billion, a PE ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $92.26 and a twelve month high of $136.30. The firm has a fifty day simple moving average of $123.98 and a 200 day simple moving average of $118.71.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the company posted $2.02 EPS. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares in the company, valued at approximately $70,740,911.34. The trade was a 1.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 141,757 shares of company stock valued at $17,569,112. 0.27% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.